APA (7th ed.) Citation

Carreño, J. M., Lerman, B., Singh, G., Abbad, A., Yellin, T., Ehrenhaus, J., . . . Krammer, F. XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies. American Society for Microbiology.

Chicago Style (17th ed.) Citation

Carreño, Juan Manuel, et al. XBB.1.5 Monovalent Vaccine Induces Lasting Cross-reactive Responses to SARS-CoV-2 Variants Such as HV.1 and JN.1, as Well as SARS-CoV-1, but Elicits Limited XBB.1.5 Specific Antibodies. American Society for Microbiology.

MLA (9th ed.) Citation

Carreño, Juan Manuel, et al. XBB.1.5 Monovalent Vaccine Induces Lasting Cross-reactive Responses to SARS-CoV-2 Variants Such as HV.1 and JN.1, as Well as SARS-CoV-1, but Elicits Limited XBB.1.5 Specific Antibodies. American Society for Microbiology.